

# Amedeo Lonardo

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2339932/amedeo-lonardo-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150  
papers

9,874  
citations

54  
h-index

97  
g-index

169  
ext. papers

12,209  
ext. citations

5  
avg, IF

6.63  
L-index

#	Paper	IF	Citations
150	Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 589-600	13.4	640
149	Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 181-90	3.3	430
148	Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 936-44	4	378
147	Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. <i>Gastroenterology</i> , <b>2004</b> , 126, 586-97	13.3	368
146	Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2009</b> , 24, 830-40	4	364
145	Sex and gender: modifiers of health, disease, and medicine. <i>Lancet, The</i> , <b>2020</b> , 396, 565-582	40	347
144	Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 335-352	13.4	298
143	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 997-1006	3.3	279
142	From NAFLD in clinical practice to answers from guidelines. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 859-71	13.4	249
141	Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. <i>Hepatology</i> , <b>2019</b> , 70, 1457-1469	11.2	238
140	NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. <i>Advances in Therapy</i> , <b>2017</b> , 34, 1291-1326	4.1	232
139	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 471-483	3.3	179
138	Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , <b>2018</b> , 79, 64-76	12.7	171
137	Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. <i>Nature Reviews Endocrinology</i> , <b>2018</b> , 14, 99-114	15.2	170
136	Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 1724-45	5.6	160
135	Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 272-82	3.3	159
134	Nonalcoholic fatty liver disease and aging: epidemiology to management. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 14185-204	5.6	158

133	Non-alcoholic fatty liver disease and risk of cardiovascular disease. <i>Metabolism: Clinical and Experimental</i> , <b>2016</b> , 65, 1136-50	12.7	152
132	Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. <i>Atherosclerosis</i> , <b>2012</b> , 221, 496-502	3.1	141
131	Liver and diabetes. A vicious circle. <i>Hepatology Research</i> , <b>2013</b> , 43, 51-64	5.1	130
130	Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. <i>Liver International</i> , <b>2012</b> , 32, 1242-52	7.9	124
129	Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 3410-7	5.6	121
128	Hepatitis C and steatosis: a reappraisal. <i>Journal of Viral Hepatitis</i> , <b>2006</b> , 13, 73-80	3.4	117
127	Hepatic steatosis and insulin resistance: does etiology make a difference?. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 190-6	13.4	116
126	Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. <i>Digestive Diseases and Sciences</i> , <b>2003</b> , 48, 2173-81	4	107
125	Endocrine and liver interaction: the role of endocrine pathways in NASH. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2009</b> , 6, 236-47	24.2	100
124	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. <i>Atherosclerosis</i> , <b>2014</b> , 232, 99-109	3.1	97
123	Statins in liver disease: a molehill, an iceberg, or neither?. <i>Hepatology</i> , <b>2008</b> , 48, 662-9	11.2	97
122	Endocrine NAFLD: a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 1196-207	13.4	97
121	Nonalcoholic fatty liver disease: Evolving paradigms. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 6571-6592	5.9	92
120	Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. <i>Digestive and Liver Disease</i> , <b>2002</b> , 34, 204-11	3.3	87
119	Fatty liver in heterozygous hypobetalipoproteinemia caused by a novel truncated form of apolipoprotein B. <i>Gastroenterology</i> , <b>1996</b> , 111, 1125-33	13.3	82
118	The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. <i>Hepatology Research</i> , <b>2011</b> , 41, 1071-1087	5.1	82
117	Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. <i>Metabolism: Clinical and Experimental</i> , <b>2017</b> , 72, 57-65	12.7	80
116	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 5177-5192	3.3	80

115	Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2015</b> , 9, 603-27	4.2	79
114	Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 1246-67	4	75
113	Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2005</b> , 20, 1176-84	4	70
112	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 5177-5192	3.3	70
111	Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 9674-9693	5.6	69
110	Right colon adenocarcinoma presenting as Bacteroides Fragilis liver abscesses. <i>Journal of Clinical Gastroenterology</i> , <b>1992</b> , 14, 335-8	3	68
109	Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 7089-103	5.6	66
108	Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , <b>2009</b> , 41, 823-8	3.3	61
107	Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. <i>Hepatology</i> , <b>2016</b> , 64, 1388-9	11.2	60
106	Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going?. <i>Digestive Diseases</i> , <b>1999</b> , 17, 80-9	3.2	59
105	Review article: hepatic steatosis and insulin resistance. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 22 Suppl 2, 64-70	6.1	58
104	Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2015</b> , 9, 629-50	4.2	57
103	Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?. <i>Internal and Emergency Medicine</i> , <b>2013</b> , 8, 297-305	3.7	57
102	Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. <i>Clinical Science</i> , <b>2008</b> , 115, 1-12	6.5	57
101	Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. <i>Gut</i> , <b>2022</b> , 71, 156-162	19.2	56
100	Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2007</b> , 17, 684-98	4.5	56
99	Metabolic alterations and chronic hepatitis C: treatment strategies. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 2215-34	4	55
98	The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans. <i>Advances in Therapy</i> , <b>2016</b> , 33, 291-319	4.1	54

97	Hepatitis C and diabetes: the inevitable coincidence?. <i>Expert Review of Anti-Infective Therapy</i> , <b>2009</b> , 7, 293-308	5.5	54
96	Should nonalcoholic fatty liver disease be renamed?. <i>Digestive Diseases</i> , <b>2005</b> , 23, 72-82	3.2	54
95	Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?. <i>Endocrine</i> , <b>2016</b> , 51, 211-21	4	53
94	Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene. <i>Journal of Lipid Research</i> , <b>2001</b> , 42, 1552-1561	6.3	53
93	Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?. <i>Journal of Endocrinological Investigation</i> , <b>2015</b> , 38, 817-25	5.2	52
92	A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5). <i>Journal of Hepatology</i> , <b>2000</b> , 33, 361-70	13.4	51
91	Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Thyroid</i> , <b>2018</b> , 28, 1270-1284	6.2	50
90	Potential for statins in the chemoprevention and management of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2012</b> , 27, 1654-64	4	50
89	Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. <i>Metabolites</i> , <b>2021</b> , 11,	5.6	50
88	Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2011</b> , 5, 279-89 <sup>4.2</sup>	4.2	48
87	Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , <b>2018</b> , 87, 1-12	12.7	48
86	Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17, 217	6.3	47
85	Fatty liver, carotid disease and gallstones: a study of age-related associations. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 5826-33	5.6	46
84	Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	45
83	Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 5177-92	3.3	45
82	Review article: the metabolic syndrome and non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 22 Suppl 2, 31-6	6.1	44
81	NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	43
80	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 333-42	3.3	42

79	Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2000</b> , 15, 775-82	4	42
78	A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?. <i>Acta Diabetologica</i> , <b>2019</b> , 56, 385-396	3.9	42
77	Are routine duodenal and antral biopsies useful in the management of "functional" dyspepsia? A diagnostic and therapeutic study. <i>Journal of Clinical Gastroenterology</i> , <b>1993</b> , 17, 101-8	3	40
76	Gender, fatty liver and GGT. <i>Hepatology</i> , <b>2006</b> , 44, 278-9	11.2	38
75	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 351-367	4.2	34
74	Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. <i>Annals of Hepatology</i> , <b>2020</b> , 19, 359-366	3.1	33
73	Growth hormone plasma levels in nonalcoholic fatty liver disease. <i>American Journal of Gastroenterology</i> , <b>2002</b> , 97, 1071-2	0.7	33
72	Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. <i>Atherosclerosis</i> , <b>2019</b> , 284, 66-74	3.1	31
71	History of Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	30
70	Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeeer" in the Spotlight. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17, 355	6.3	30
69	Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2013</b> , 37, 353-8	2.4	29
68	Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. <i>Archives of Medical Research</i> , <b>2011</b> , 42, 337-53	6.6	29
67	Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , <b>1998</b> , 43, 2489-92	4	27
66	Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 462-470	3.3	26
65	Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 1458-1468	5.6	26
64	Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. <i>Advances in Therapy</i> , <b>2020</b> , 37, 1910-1932	4.1	25
63	Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. <i>Metabolism: Clinical and Experimental</i> , <b>2019</b> , 96, 56-65	12.7	24
62	Hepatitis C virus-infected patients are spared from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2009</b> , 23, 273-8		24



61	Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver. <i>Aids</i> , <b>2017</b> , 31 Suppl 2, S147-S156	3.5	23
60	A critical appraisal of the use of ultrasound in hepatic steatosis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2019</b> , 13, 667-681	4.2	23
59	Dysmetabolic changes associated with HCV: a distinct syndrome?. <i>Internal and Emergency Medicine</i> , <b>2008</b> , 3, 99-108	3.7	22
58	Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	22
57	Relationship of serum fetuin-A levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography. <i>Metabolic Syndrome and Related Disorders</i> , <b>2013</b> , 11, 289-95	2.6	21
56	HCV and diabetes. A two-question-based reappraisal. <i>Digestive and Liver Disease</i> , <b>2007</b> , 39, 753-61	3.3	21
55	Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. <i>Hepatology</i> , <b>2004</b> , 39, 1748; author reply 1749	11.2	18
54	Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. <i>Future Medicinal Chemistry</i> , <b>2019</b> , 11, 2171-2192	4.1	18
53	Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease. <i>Archives of Medical Research</i> , <b>2011</b> , 42, 690-7	6.6	16
52	Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2010</b> , 5, 403-423	4.1	16
51	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. <i>Metabolism: Clinical and Experimental</i> , <b>2020</b> , 113, 154413	12.7	16
50	Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure. <i>Medicine (United States)</i> , <b>2016</b> , 95, e2760	1.8	15
49	Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: chance tetrad or association by necessity?. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 288-9	3.3	15
48	Pediatric gallstone disease in familial hypobetalipoproteinemia. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 188-91	13.4	14
47	Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease?. <i>Diseases (Basel, Switzerland)</i> , <b>2018</b> , 6,	4.4	13
46	The wide spectrum of steatohepatitis: a report of four cases and a review of the literature. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2004</b> , 16, 1043-50	2.2	13
45	Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. <i>Advances in Therapy</i> , <b>2021</b> , 38, 2130-2158	4.1	13
44	If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis?. <i>Digestive and Liver Disease</i> , <b>2012</b> , 44, 451-2	3.3	11

43	The hepatitis C virus-associated dysmetabolic syndrome. <i>Hepatology</i> , <b>2008</b> , 48, 1018-9; author reply 1019	11.2	11
42	The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 1200-1; author reply 1201-2	0.7	11
41	Is cholangiocarcinoma another complication of insulin resistance: a report of three cases. <i>Metabolic Syndrome and Related Disorders</i> , <b>2007</b> , 5, 194-202	2.6	10
40	Perspectives of nonalcoholic fatty liver disease research: a personal point of view <b>2020</b> , 1, 85-107		10
39	Statins and HCV: a complex issue. <i>Hepatology</i> , <b>2007</b> , 45, 257	11.2	9
38	Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	9
37	NAFLD and cardiovascular risk: direct evidence for the tale of two ages. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 1851-2	0.7	8
36	Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?. <i>Internal and Emergency Medicine</i> , <b>2009</b> , 4, 71-3	3.7	8
35	Apolipoprotein synthesis in nonalcoholic steatohepatitis. <i>Hepatology</i> , <b>2002</b> , 36, 514-5; author reply 515	11.2	8
34	Isolated jejunal Crohn's disease in a young adult presenting as fever of unknown origin. <i>American Journal of Gastroenterology</i> , <b>1998</b> , 93, 2285-7	0.7	8
33	Hypothyroidism and nonalcoholic fatty liver disease - a chance association?. <i>Hormone Molecular Biology and Clinical Investigation</i> , <b>2018</b> , 41,	1.3	8
32	Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: what do they mean and do they agree?. <i>Hepatology</i> , <b>2011</b> , 53, 2142-3; author reply 2143	11.2	7
31	Semi-Quantitative Ultrasonographic Evaluation of NAFLD. <i>Current Pharmaceutical Design</i> , <b>2020</b> , 26, 3915-3927	5.3	7
30	Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma. <i>Journal of Clinical Virology</i> , <b>2015</b> , 69, 74-7	14.5	6
29	Solitary Peutz-Jeghers type polyp of the stomach. <i>Endoscopy</i> , <b>1990</b> , 22, 153	3.4	6
28	Familial history in IBD. <i>Digestive Diseases and Sciences</i> , <b>1985</b> , 30, 410	4	6
27	Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1399-1401	3.3	6
26	Primary lymphoma of the spleen mimicking simple benign cysts: contrast-enhanced ultrasonography and other imaging findings. <i>Journal of Medical Ultrasonics (2001)</i> , <b>2015</b> , 42, 251-5	1.4	5



25	The neck-liver axis. Madelung disease as further evidence for an impact of body fat distribution on hepatic histology. <i>Hepatology</i> , <b>2008</b> , 47, 361-2	11.2	5
24	Chicken or egg turned into head or belly. <i>Journal of Hepatology</i> , <b>2006</b> , 45, 454-456	13.4	5
23	17 Beta-estradiol prevents cytotoxicity from hydrophobic bile acids in HepG2 and WRL-68 cell cultures. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2006</b> , 21, 894-901	4	5
22	Intestinal Wegener's granulomatosis in a patient with severe alpha-1-antitrypsin deficiency resulting from a unique combination of two deficiency alleles (PiZ and PiMProcida). <i>European Journal of Gastroenterology and Hepatology</i> , <b>2002</b> , 14, 1389-92	2.2	5
21	Nonalcoholic fatty liver disease in HIV-infected persons: epidemiology and the role of nucleoside reverse transcriptase inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2010</b> , 53, 278; author reply 278-81	3.1	4
20	Of liver, whisky and plants: a requiem for colchicine in alcoholic cirrhosis?. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2002</b> , 14, 355-8	2.2	4
19	How Much Vitamin D is Too Much? A Case Report and Review of the Literature. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , <b>2021</b> , 21, 1653-1659	2.2	4
18	Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. <i>Hepatology Research</i> , <b>2012</b> , 42, 945	5.1	3
17	Portal vein thrombosis (PVT) associated with oral contraceptive steroids (OCS). <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1994</b> , 9, 314	4	3
16	Liver cirrhosis as a diabetogenic condition. <i>Digestive Diseases and Sciences</i> , <b>1986</b> , 31, 111	4	3
15	Gamma glutamyl transferase: A novel cardiovascular outfit for an old liver test. <i>Indian Journal of Medical Research</i> , <b>2016</b> , 143, 4-7	2.9	3
14	Lack of correlation between the laboratory findings and a series of steps in the clinical severity of chronic liver disease. <i>Research in Clinic and Laboratory</i> , <b>1984</b> , 14, 641-8		3
13	NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk. <i>Hepatology</i> , <b>2017</b> , 65, 2122-2123	11.2	2
12	Methodological Tools for Exploring Novel Biopharmaceutical Approaches to the Metabolic Syndrome and Related Disorders : A Commentary on: Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. A Focus on Early Phase Clinical Drug Development, Second Edition. <i>Diabetes Therapy</i> , <b>2020</b> , 11, 773-777	3.6	1
11	Noninvasive diagnosis of nonalcoholic fatty liver disease, is the more expensive the better?. <i>AME Medical Journal</i> , <b>2017</b> , 2, 171-171	1	1
10	Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?. <i>Liver International</i> , <b>2015</b> , 35, 2340-1	7.9	1
9	Fatty liver and carotid intimal thickening: a tale of two ages?. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 1061	0.7	1
8	Article Commentary: Insulin Resistance, Type 2 Diabetes and Chronic Liver Disease. A Deadly Trio. <i>Clinical Medicine: Endocrinology and Diabetes</i> , <b>2009</b> , 2, CMED.S3518		1

7	Metabolic-Associated Fatty Liver Disease Is Highly Prevalent in the Postacute COVID Syndrome.. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofac003	1	1
6	Alcohol and Steatosis: The Japanese Paradox. <i>EBioMedicine</i> , <b>2016</b> , 8, 23-24	8.8	1
5	Use of procalcitonin for the differential diagnosis of fever in cancer patients: an observational study. <i>Italian Journal of Medicine</i> , <b>2013</b> , 166-171	0.5	
4	Is insulin resistance a pathogenic co-factor in hepatitis C virus-related disease and hepatocellular carcinoma?. <i>Digestive and Liver Disease</i> , <b>2002</b> , 34, 151	3.3	
3	High prevalence of duodenal ulcer in Indochinese immigrants attending an Australian university hospital. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1994</b> , 9, 663	4	
2	HCV treatment in patients with metabolic syndrome <b>2013</b> , 86-97		
1	Clearing hepatitis C virus with direct antiviral agents reduces cardiovascular events in patients with prediabetes. Commentary to Sasso and colleagues. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2021</b> , 31, 2354-2357	4.5	